Science News
from research organizations

Major step toward an Alzheimer's vaccine

Date:
January 15, 2013
Source:
Université Laval
Summary:
Medical researchers have discovered a way to stimulate the brain's natural defense mechanisms in people with Alzheimer's disease. This major breakthrough opens the door to the development of a treatment for Alzheimer's disease and a vaccine to prevent the illness.
Share:
         
Total shares:  
FULL STORY

Medical researchers have discovered a way to stimulate the brain's natural defense mechanisms in people with Alzheimer's disease. This major breakthrough opens the door to the development of a treatment for Alzheimer's disease and a vaccine to prevent the illness.
Credit: © shefkate / Fotolia

A team of researchers from Université Laval, CHU de Québec, and pharmaceutical firm GlaxoSmithKline (GSK) has discovered a way to stimulate the brain's natural defense mechanisms in people with Alzheimer's disease. This major breakthrough, details of which are presented January 15 in an early online edition of the Proceedings of the National Academy of Sciences (PNAS), opens the door to the development of a treatment for Alzheimer's disease and a vaccine to prevent the illness.

One of the main characteristics of Alzheimer's disease is the production in the brain of a toxic molecule known as amyloid beta. Microglial cells, the nervous system's defenders, are unable to eliminate this substance, which forms deposits called senile plaques.

The team led by Dr. Serge Rivest, professor at Université Laval's Faculty of Medicine and researcher at the CHU de Québec research center, identified a molecule that stimulates the activity of the brain's immune cells. The molecule, known as MPL (monophosphoryl lipid A), has been used extensively as a vaccine adjuvant by GSK for many years, and its safety is well established.

In mice with Alzheimer's symptoms, weekly injections of MPL over a twelve-week period eliminated up to 80% of senile plaques. In addition, tests measuring the mice's ability to learn new tasks showed significant improvement in cognitive function over the same period.

The researchers see two potential uses for MPL. It could be administered by intramuscular injection to people with Alzheimer's disease to slow the progression of the illness. It could also be incorporated into a vaccine designed to stimulate the production of antibodies against amyloid beta. "The vaccine could be given to people who already have the disease to stimulate their natural immunity," said Serge Rivest. "It could also be administered as a preventive measure to people with risk factors for Alzheimer's disease."

"When our team started working on Alzheimer's disease a decade ago, our goal was to develop better treatment for Alzheimer's patients," explained Professor Rivest. "With the discovery announced today, I think we're close to our objective."


Story Source:

The above story is based on materials provided by Université Laval. Note: Materials may be edited for content and length.


Journal Reference:

  1. Jean-Philippe Michaud, Maxime Hallé, Antoine Lampron, Peter Thériault, Paul Préfontaine, Mohammed Filali, Pascale Tribout-Jover, Anne-Marie Lanteigne, Rachel Jodoin, Christopher Cluff, Vincent Brichard, Rémi Palmantier, Anthony Pilorget, Daniel Larocque, and Serge Rivest. Toll-like receptor 4 stimulation with the detoxified ligand monophosphoryl lipid A improves Alzheimer’s disease-related pathology. PNAS, January 15, 2013 DOI: 10.1073/pnas.1215165110

Cite This Page:

Université Laval. "Major step toward an Alzheimer's vaccine." ScienceDaily. ScienceDaily, 15 January 2013. <www.sciencedaily.com/releases/2013/01/130115143852.htm>.
Université Laval. (2013, January 15). Major step toward an Alzheimer's vaccine. ScienceDaily. Retrieved May 3, 2015 from www.sciencedaily.com/releases/2013/01/130115143852.htm
Université Laval. "Major step toward an Alzheimer's vaccine." ScienceDaily. www.sciencedaily.com/releases/2013/01/130115143852.htm (accessed May 3, 2015).

Share This Page:


Recommended Content
 


Mind & Brain News
May 3, 2015

Latest Headlines
updated 12:56 pm ET